, an analogue of U-50488H, is a selective K-opioid receptor agonist. The analgesic activities of spiradoline found in various antinociceptive tests were higher than those of morphine and U-50488H (1, 2). Spiradoline is a mixture of the (-) and (+) enantiomers, the former enan tiomer being a K-opioid receptor agonist and the latter, a ,u-opioid receptor agonist (1). However, spiradoline has the same pharmacological properties as U-50488H in terms of pA2 for naloxone antagonism, cross-tolerance, and physical dependence (1, 2). Receptor-binding studies have shown the selectivity of spiradoline for tc-receptors to be 84 times that for p-receptors and 100 times that for 6-receptors (3). These reports indicate that spiradoline, like U-50488H, is a highly selective K-opioid -receptor agonist.
the tc-opioid-receptor agonists spiradoline and U-50488H were not altered by haloperidol or L-dopa, whereas morphine analgesia was enhanced by haloperidol but attenuated by L-dopa. Spiradoline decreased spontaneous locomotor activity in mice and inhibited methamphetamine or morphine-induced locomotor activity. In contrast, morphine given alone increased locomotor activity and enhanced methamphetamine induced locomotor activity.
In a neurochemical study, spiradoline decreased the amounts of dopamine metabolites in the striatum, but did not alter them in the brainstem and cerebral cortex. Morphine increased the dopamine metabolite contents in all three brain regions tested. These results suggest that inhibition of the dopaminergic pathway in the brain by spiradoline may be involved in its suppression of locomotor activ ity, but not in its analgesia; whereas, stimulation of the dopaminergic pathway by morphine seems to func tion in both behaviors: enhancement of locomotor activity and inhibition of analgesia.
Keywords: Spiradoline, ir-Opioid-receptor agonist, Dopaminergic system, Analgesia, Locomotor activity Spiradoline mesylate, (5a,7a,8;3)-(±)-3,4-dichloro-N [7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl] methansulfo nate, an analogue of U-50488H, is a selective K-opioid receptor agonist. The analgesic activities of spiradoline found in various antinociceptive tests were higher than those of morphine and U-50488H (1, 2) . Spiradoline is a mixture of the (-) and (+) enantiomers, the former enan tiomer being a K-opioid receptor agonist and the latter, a ,u-opioid receptor agonist (1) . However, spiradoline has the same pharmacological properties as U-50488H in terms of pA2 for naloxone antagonism, cross-tolerance, and physical dependence (1, 2) . Receptor-binding studies have shown the selectivity of spiradoline for tc-receptors to be 84 times that for p-receptors and 100 times that for 6-receptors (3) . These reports indicate that spiradoline, like U-50488H, is a highly selective K-opioid -receptor agonist.
Many reports based on results of behavioral, neuro chemical, and electrophysiological studies show that the actions of opioids on dopamine (DA) neurons in the brain are primarily related to p-opioid receptors. Little is, however, known about the actions of ic-opioid-receptor agonists on DA neuronal systems in the brain. Early results of pharmacological studies of various compounds with ic-opioid-receptor agonists, such as pentazocine, cyclazocine, ethylcyclazocine, and ketazocine, were incon clusive because of the lack of specificity towards K-opioid receptors. The development of U-50488H has made pos sible the unequivocal examination of the role of c-opioid receptors in modulating central DA neuron activity. U 50488H did not alter the activity of nigrostriatal DA neu rons in normal rat brain, but did decrease the DA neuron activities in haloperidol-treated rats, in which the nigro striatal DA neuron activities had been stimulated (4) . In contrast, the putative p-opioid-receptor agonist morphine stimulated both nigrostriatal and mesolimbic DA neuron activities (5) .
In many cases, however, the neurochemical and behav ioral investigations have been performed independently, without attempting to correlate them to each other. There fore, we first assessed the effects of a new rc-opioid-recep tor agonist, spiradoline, on analgesia and locomotor activ ity; and we measured DA and its metabolites to clarify the relationship between DA metabolism and behavioral func tions. We also compared the neurochemical and behav ioral effects of spiradoline with those of the p-agonist mor phine and the K-agonist U-50488H.
MATERIALS AND METHODS

Animals
Four-week-old male ICR strain mice, purchased from Charles River Japan Co. (Atsugi), were given free access to commercial solid food (MF: Oriental Yeast Co., Tokyo) and city drinking water in an animal room in which conditions were controlled at 22±21C, 55± 5076 relative humidity, and a 12-hr light-dark cycle (lights on 07:00-19:00). The mice were housed in a holding room for 4 or 5 days before the tests for analgesic activity and were denied food on the morning of the test day.
Measurement of locomotor activity
The locomotor activity of each mouse was measured with a mouse ambulometer (Ohara Medical Co., Tokyo) by the tilting cage method (6) . The mouse was placed in an open round cage, 25 cm in diameter. Whenever the mouse moved, the cage tilted. The number of tilts was recorded as locomotor activity through three electromag netic counters set at 0.5-cm intervals around the open cage.
In the case of spiradoline, locomotor activity was meas ured for 30 min immediately after an intraperitoneal injec tion of the compound in order to elucidate its inhibitory activity. In the case of morphine, the intraperitoneal injec tion was done when the exploratory behavior of the mouse had ceased, after which locomotor activity was measured for 180 min. In the combination study done with the DA agonist methamphetamine and the analgesic, 10 mg/kg of spiradoline or morphine was first given in traperitoneally, and then methamphetamine at 2 mg/kg was immediately injected subcutaneously. Locomotor ac tivity was thereafter measured for 240 min at intervals of 10 min. In the combination study done with the two anal gesics, 3, 10 or 30 mg/kg of spiradoline was first given in traperitoneally, and then 10 mg/kg of morphine was in jected subcutaneously. Locomotor activity was thereafter measured for 180 min.
Assay of analgesic activity
The mouse tail-pinch method was used. A commercial arterial clamp (Natsume Industrial Co., Tokyo) was clipped to the base of the tail, and the time that elapsed until the mouse turned and bit the clamp was recorded as the analgesic latency time. The clamp test was repeated 2 to 3 times with resting periods between tests before ad ministration of the test drug in order to establish the base line of the analgesic response. At the final trial, mice that showed latency times of more than 2 sec were dropped from the studies. The maximal cut off time was 15 sec.
Spiradoline and U-50488H were injected at 15 min, and morphine at 30 min, before the analgesic test in order to obtain the maximal response. Intraperitoneal injection of the DA agonist L-dopa (100 mg/kg) or subcutaneous injec tion of the DA antagonist haloperidol (1 mg/kg) was made 45 min before the analgesic test; i.e., morphine was administered at 15 min or spiradoline at 30 min after the DA agonist or antagonist.
Measurement of brain dopamine and its metabolites
Brain enzymes were inactivated by giving 5-kW micro wave irradiation per mouse for 0.6 sec with a microwave applicator (L-2000, Shinnihonmusen, Tokyo). There after, the whole brain was removed immediately and placed on aluminum foil chilled to 01C with crushed ice. Dissection using a modification of the method of Glowin ski and Iversen (7) gave 5 regions: the cerebrum, brain stem, hippocampus, striatum and cortex. To homogenize the brainstem, cortex, and striatum, each of those tissues was sonicated in 0.5 ml of 0.05 N perchloric acid contain ing 1.25 mM EDTA with 50 ng/ml deoxyepinephrine as the internal standard. Thirty minutes later, the homog enate was centrifuged for 15 min at 12,000 rpm and 4C. A 250 pl portion of the supernatant was then added to the same volume of chloroform, and the whole mixture mix ed for 30 sec. After a 15-min centrifugation at 12,000 rpm and 41C, a 10-,ul sample of the upper phase was analyzed by high performance liquid chromatography (HPLC).
DA, DOPAC (dihydroxyphenylacetic acid) and HVA (homovanillic acid) were assayed by the BAS HPLC sys tem (LCEC II) equipped with an electrochemical detec tor. The HPLC system consisted of an ODS reverse phase analytical column (30 mm in diameter, 15-cm long), a tem perature controller (371C), and a glassy carbon detector (700-mV loaded potential). One liter of the mobile phase contained 21 g citrate anhydrate, 10 ml 5 mM EDTA, 3 ml 10 N NaOH, 80 mg sodium octyl sulphate, and 60 ml acetonitrile. The flow rate was 0.8 ml/min.
Drugs
The doses of spiradoline mesylate (Upjohn, Kalama zoo, MI, USA), morphine HCl (Sankyo Co., Tokyo), and U-50488H (Upjohn) were expressed as the weights of the free bases. These analgesics were dissolved in 0.907o NaCI solution (saline) and then injected to the mice in tramuscularly at 2 ml/kg or intraperitoneally at 5 ml/kg. Methamphetamine (Philopon~, Dainippon Pharmaceuti cal Co., Osaka) was dissolved in saline at 2 mg/5 ml, and then injected at 5 ml/kg.
Statistical analyses
A non-parametric method of statistical analysis was used for the behavioral analgesic studies. The Kraskal Wallis test was first done to show the significances of the differences among the groups (P < 0.05), and this was fol lowed by Dunnett's multiple test. For the neurochemical studies, a parametric method was used, Dunnett's test being utilized only when the one way analysis of variances (ANOVA) was significant (P <0.05).
behavior to determine the decreasing effect clearly.
Spiradoline had no effect on locomotor activity at 3 and 10 mg/kg, i.p., but decreased it significantly at 30 mg/kg Fig. 1 . Effects of morphine (left) and spiradoline (right) on methamphetamine-induced locomotor activity in mice. A 10 mg/kg dose of morphine or spiradoline was given intraperitoneally to mice after exploratory behavior ceased. Immediately after 2 mg/kg of methamphetamine was injected subcutanously, locomotor activity was measured for 240 min at intervals of 10 min. Data are shown as means±S.E.M. of 10 animals.
RESULTS
Effects of morphine and spiradoline on locomotor activity The effect of morphine on locomotor activity was meas ured for 3 hr after exploratory behavior (locomotor, rear ing, and grooming activity) had ended in order to evalu ate the increasing effect clearly. Morphine caused a dose dependent, statistically significant increase in locomotor activity at 10 and 30 mg/kg, i.p. (Table 1 ). In particular, the 30 mg/kg dose produced 1859 counts/3 hr for locomo tor activity, as compared to the 68 counts/3 hr of the vehi cle control.
Because a preliminary study showed that locomotor ac tivity was inhibited by spiradoline, this activity was meas ured for 30 min during the enhancement of exploratory (18 counts/30 min) as compared to the effect of the saline vehicle control (101 counts/30 min).
Effects of morphine and spiradoline on methampheta mine-induced locomotor activity Locomotor activity was markedly increased by 2 mg/kg, s.c. of methamphetamine alone (1657 counts/3 hr, P<0.001) and by 10 mg/kg, i.p. of morphine alone (718 counts/3 hr, P<0.01), as compared to the value for the saline vehicle control (55 counts/3 hr). When mor phine was given to mice together with meth amphetamine, there was a remarkable increase in locomotor activity (6930 counts/3 hr, P < 0.01 vs. methamphetamine alone and P<0.001 vs. morphine alone). This increase was more than additive (Fig. 1, left) .
The effect of spiradoline alone at 10 mg/kg, i.p. on locomotor activity was similar to that of the vehicle con trol (111 counts/3 hr), but spiradoline inhibited metham phetamine-induced locomotor activity completely (Fig. 1,  right) .
Effect of spiradoline on morphine-induced locomotor activity
As shown in Fig. 2 , locomotor activity was markedly increased by 10 mg/kg, s.c. of morphine (1776 counts/3 hr). Pretreatment of mice with 3 and 10 mg/kg, i.p. of spiradoline produced no significant changes in morphine induced locomotor activity, the respective activities being 2015 and 1279 counts/3 hr, whereas 30 mg/kg blocked morphine-induced locomotor activity significantly (284 counts/3 hr, P < 0.001).
Effects of L-dopa and haloperidol on morphine-, spirado line and U-50488H-induced analgesia
Neither the DA agonist L-dopa nor the DA antagonist haloperidol alone produced significant changes in the latency time following nociceptive stimulation by the mouse tail-pinch test (Fig. 3) . Morphine at up to 6 mg/kg, i.m. prolonged the latency in a dose-dependent manner. The latency time of 6 mg/kg morphine was sig nificantly shortened by pretreatment with L-dopa, but that of 3 mg/kg was not. In contrast, the latency time of 3 mg/kg morphine was much more enhanced by pretreat ment with haloperidol, and that of 6 mg/kg was near the maximal cut-off time, 15 sec.
Spiradoline at 0.3 and 0.6 mg/kg significantly pro longed latency (Fig. 4) , but neither L-dopa nor haloperi dol affected the prolongation produced by spiradoline. Table 2 . DA, DOPAC and HVA contents in the brainstem, cerebral cortex and striatum after the intramuscular injection of morphine Table 3 . DA, DOPAC and HVA levels in the brainstem, cerebral cortex and striatum after the intramuscular injection of spiradoline
The prolonged latency by 6 and 12 mg/kg of U-50488H, a reputed typical K-opioid-receptor agonist, was also not al tered by L-dopa or haloperidol. Haloperidol rather tend ed to shorten the latency time of 12 mg/kg U-50488H (Fig. 5) .
Effects of morphine and spiradoline on DA, DOPAC, and HVA contents in the brainstem, cerebral cortex and striatum Morphine at 3 and 6 mg/kg, i.m. caused no significant changes in DA contents of the brainstem, cerebral cortex, and striatum (Table 2) . A 3 mg/kg dose of morphine sig nificantly increased the amounts of DOPAC and HVA in the striatum, but there was a tendency to increase both DA metabolites in the other two brain regions. A 6 mg/kg dose of morphine increased the two DA metabolite con tents markedly in all three regions.
The DA, DOPAC, and HVA contents in the brainstem and cerebral cortex were not changed significantly 15 or 30 min after injection of 0.3 or 0.6 mg/kg of spiradoline (Table 3) . The striatal DA, DOPAC, and HVA contents tended to decrease 30 min after the injection of 0.3 or 0.6 mg/kg spiradoline and showed significant decreases 30 min after the larger dose.
DISCUSSION
The results reported here demonstrate clearly that the putative p-opioid receptor agonist morphine increased locomotor activity and evoked analgesia in response to tail-pinch nociception, whereas the K-opioid-receptor agonist spiradoline decreased locomotor activity and evoked analgesia. This suggests that the p and r-opioid receptor agonists have different pharmacological actions. In particular, the two non-peptide opioids appear to have opposite actions on locomotor activity. Indeed, we found marked, dose-dependent inhibition of morphine-induced locomotor activity by spiradoline in mice. In contrast, both morphine and spiradoline had analgesic action in response to pressure nociception by the mouse tail-pinch; the analgesic potency of the K-opioid receptor agonist was about 10 times that of the p-opioid receptor agonist. However, there are distinct profiles even in both analgesic actions: 1) Spiradolone analgesia is blocked by much higher amounts of naloxone than is morphine analgesia (1). 2) There is no cross-tolerance between these anal gesics (1, 2). 3) Spiradoline analgesia observed in the mouse tail-pinch test is potentiated by re-uptake inhibi tors of noradrenaline (NE) such as imipramine and desipramine, but morphine analgesia is not (8) . The ac tions of spiradoline on the central nervous system includ ing analgesia and locomotor activity are therefore distinct from those of morphine, presumably because they work through different opioid receptors. Some reports also have shown that K-opioid-receptor agonists evoke potent diuretic activity and sedation (9-11), thereby differing from the p-opioid-receptor agonists.
In our present study, morphine potentiated the loco motor activity of the DA agonist methamphetamine in a more than additive manner. Moreover, the morphine anal gesia was inhibited by the DA agonist L-dopa, but poten tiated by the DA receptor antagonist haloperidol. These behavioral results suggest that the activation of DA neu rons stimulates the motor neuron system and depresses the analgesic neuron system. In fact, morphine increased the amounts of the DA metabolites DOPAC and HVA sig nificantly in the brain stem, cerebral cortex, and striatum. That is, the activation of DA neurons by morphine in the neurochemical study may be explained by its increasing effect on locomotor activity and inhibitory effect on anal gesia. However, there are conflicting reports on DA agents and morphine analgesia (12) (13) (14) : Treatment with the DA agonist apomorphine has been reported to cause inhibition of, enhancement of, or to have no effect on morphine analgesia depending on the dose of the DA ago nist; the low doses (0.1 mg/kg or less) of apomorphine inhibit presynaptic "autoreceptors", thereby depressing DA release in rats, whereas the higher doses (more than 0.3 mg/kg) stimulate postsynaptic DA receptors, thereby enhancing DA neuron actions (15) . In addition, spiper one, a putative DA receptor antagonist, has been report ed to potentiate morphine analgesia at 0.1 mg/kg, but this DA receptor antagonist neither potentiates mor phine-induced analgesia nor impairs morphine-induced rotarod performance at 0.03 mg/kg, a dose sufficient to block postsynaptic DA receptors. It was concluded that 0.1 mg/kg of spiperone caused sedation/ataxia by block ing DA postsynaptic receptors, and the sedation/ataxia appears to enhance morphine analgesia (16) . Much effort will be needed to characterize morphine analgesia with regard to central DA neurotransmission.
On the basis of reports (17, 18) on dosage, we used 100 mg/kg, s.c. Of L-dopa and 1 mg/kg, i.p. of haloperidol, respectively administered at 25 and 15 min before the anal gesia test. Our preliminary experiments using the mice treated with these DA agents apparently showed sedation and ataxia with this administration schedule. The DA agents, therefore, were given to mice 45 min before the analgesic test in order to avoid sedation and ataxia, with the result that L-dopa and haloperidol alone did not change the latency times. However, because mice treated with a DA agent, in particular haloperidol, showed slight sedation even under the revised administration schedule here, we can not say definitely that slight sedation produced by haloperidol does not contribute to morphine analgesia. In contrast, enhancement of locomotor activity by the p-opioid agonist morphine is correlated to the en hancement of DA metabolism, possibly by the stimula tion of DA release in the central nervous system as stated previously.
In our study, spiradoline inhibited methamphetamine and morphine-induced locomotor activity, and neither L dopa nor haloperidol altered spiradoline analgesia. Our behavioral results suggest that DA mechanisms are in volved in the locomotor inhibition produced by spirado line, but not in the analgesic activity of this compound. The DA agents used also had no significant effects on U 50488H analgesia, although haloperidol inhibited it some what. Thus, the antinociceptive response to K-opioid agonists may not be related to DA neuron activity. Our neurochemical study showed that spiradoline tended to decrease the DOPAC content in the striatum and also sig nificantly decreased the HVA content, although there was no dose-dependency. It is therefore suggested that striatal inhibition of DA metabolism by spiradoline may contrib ute to its inhibition of locomotion. We previously report ed that spiradoline analgesia reached a maximum 15 min after its intramuscular administration, the drug being eliminated 30 min after its administration (2). Since the peak time for DA metabolism was 30 min after the spiradoline administration, this report supports the behav ioral results that DA neuron activities may not be related to spiradoline analgesia. As shown elsewhere (8) , spirado line analgesia may be instead caused by NE and 5-HT neu ron activations.
Less is known about the effects of K-opioid-receptor agonists on the DA neuronal system in the brain than about the p-opioid agonists. Results of in vitro and in vivo electrophysiological and neurotransmitter release studies (19) (20) (21) (22) indicate that ic-opioid-receptor agonists inhibit the activities of nigrostriatal and mesolimbic DA neurons, but there are only a few reports that K-opioid receptor agonists stimulate (23) or have no effect on (24, 25) the activities of DA neurons. From brain dialysis ex periments, Di Chiara and Imperato (5) reported that the systematic administration of U-50488H produced a dose related decrease in the release of DA from the striatum and nucleus accumbens. With respect to DA neuron activ ity, there is no discrepancy between our neurochemical results on spiradoline and these reports. In the brainstem and cerebral cortex, however, spiradoline did not alter the DA, DOPAC or HVA contents, which suggests a regional difference in brain DA metabolism for spiradoline. Mor phine and other u-opioid-receptor agonists are known to have different actions on DA release in the brain: the p opioid receptor agonists stimulate activity in most brain regions, but the opioids have been reported to both stimu late and inhibit the hypothalamic DA neurons (5, 26, 27) . Manzanares et al. (4) reported that U-50488H produced a dose and time-related decrease in basal DA release in the tuberohypophysial DA neurons, but did not alter the ac tivity of the tuberoinfundibular DA neurons projecting from the hypothalamus to the posterior pituitary. There fore, it may be unexpected that spiradoline shows the regional differences in DA metabolism.
In summary, inhibition of the dopaminergic pathway in the brain by spiradoline may be involved in its inhibi tory action on locomotor activity, but not in its analgesia.
In contrast, enhancement of the dopaminergic pathway by morphine seems to function in both its increasing ef fect on locomotor activity and inhibition of its analgesia.
